La Roche Posay Laboratoire Dermatologique Effaclar Az Acne Treatment

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the treatment of acne. It effectively clears acne blemishes and penetrates pores to control existing acne lesions. Additionally, it helps prevent the formation of new acne blemishes.

Dosage and Administration

Healthcare professionals should instruct patients to shake the product well before use. Prior to application, it is essential to clean the skin thoroughly. The product should be applied as a thin layer to the entire affected area one to three times daily, depending on the patient's needs and the physician's recommendations.

To minimize the risk of excessive skin drying, it is advisable to initiate treatment with one application per day. The frequency may be gradually increased to two or three times daily as tolerated. Should the patient experience bothersome dryness or peeling, the application frequency should be reduced to once daily or every other day.

For patients who will be exposed to sunlight, it is recommended to apply sunscreen after using this product. In the event of irritation or sensitivity from either the product or the sunscreen, patients should discontinue use of both and consult a healthcare provider.

Contraindications

There are no contraindications listed for this product. However, it is imperative to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed.

Warnings and Precautions

For external use only. This product is not intended for ingestion. In the event of accidental swallowing, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately.

Healthcare professionals should advise patients to discontinue use and consult their physician if any irritation develops. It is recommended that patients utilize only one topical acne medication concurrently to minimize the risk of adverse reactions.

Side Effects

Patients should be advised that the product is for external use only. This warning is critical to ensure safe and effective use, as improper application may lead to adverse reactions or diminished therapeutic effects.

No specific adverse reactions have been reported in clinical trials or postmarketing experiences beyond the outlined warning. However, healthcare providers should remain vigilant for any unexpected reactions in patients using the product, particularly in those with sensitive skin or underlying dermatological conditions.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of La Roche Posay Laboratoire Dermatologique Effaclar Az Acne Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is recommended.

For topical application, it is suggested to initiate treatment with one application daily to minimize the risk of excessive skin drying. Dosage may be gradually increased to two or three times daily as needed or as directed by a healthcare professional. Should patients experience bothersome dryness or peeling, it is advisable to reduce the frequency of application to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of salicylic acid during pregnancy has not been established. Salicylic acid is contraindicated in pregnancy due to potential risks to the fetus, including the risk of teratogenic effects associated with its use. Pregnant women should avoid using this product unless directed by a healthcare provider. It is essential for healthcare professionals to counsel pregnant patients regarding these risks and to consider alternative treatment options when necessary.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should implement supportive measures as necessary, which may include symptomatic treatment and monitoring of vital signs.

Due to the lack of detailed overdosage information, it is recommended that healthcare professionals refer to established clinical guidelines and protocols for managing overdose situations relevant to the specific medication in question. Additionally, contacting a poison control center may provide further guidance on appropriate management strategies.

Continued vigilance and patient assessment are crucial in mitigating potential risks associated with overdosage.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Additionally, healthcare providers should inform patients about the likelihood of skin irritation and dryness when using this medication concurrently with other topical acne treatments. Patients should be counseled to use only one topical acne medication at a time to minimize the risk of irritation. This guidance will help ensure safe and effective use of the medication while reducing the potential for adverse skin reactions.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at room temperature, within the range of 68°F to 77°F (20°C to 25°C). Care must be taken to protect the product from freezing to ensure its integrity and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for La Roche Posay Laboratoire Dermatologique Effaclar Az Acne Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)